UP!

CUR $1.38   View long term graphs

Neuralstem Inc.
Type
Public
Traded as NASDAQ: CUR
Industry Biotechnology
Headquarters Menlo Park, CA
Key people
Richard J. Daly: President and CEO
Products Stem Cell Research (currently in human trials)
Website www.neuralstem.com

Neuralstem Inc. is a biotechnology company headquartered in Rockville, Maryland that specializes in developing commercial-scale production of multiple types of central nervous system stem cells.

Neuralstem's patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem’s NSI-566 spinal cord-derived stem cell therapy Phase II clinical trials for ALS concluded final surgeries in July 2014. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy. In addition to ALS, the company is also targeting major CNS conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The company has received approvals from the FDA and the Institutional Review Board of University of California, San Diego, to commence a Phase I safety trial in chronic spinal cord injury.

Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate neurons, possibly reversing pathologies associated with certain CNS conditions. The company has completed Phase Ia and Ib trials evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder (MDD), and is expecting to launch a Phase II NSI-189/MDD study in 2015. Additional indications might include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q2 2018 2018-08-06 0.00 0.00
Q1 2018 2018-05-15 0.00 -0.14
Q4 2017 2018-04-02 0.00 -0.22
Q3 2017 2017-11-08 0.00 -0.18
Q2 2017 2017-08-08 0.00 -0.39
Q1 2017 2017-05-10 0.00 -0.68
Q4 2016 2017-03-23 0.00 -0.52
Q3 2016 2016-11-08 0.00 -0.65
Q2 2016 2016-08-11 0.00 -0.52
Q1 2016 2016-05-09 0.00 -0.91

Ratings

2016-06-22 Initiated Coverage Brean Capital Buy $8.00
2016-02-20 Reiterated Rating Brean Capital Buy $8.00
2016-01-29 Initiated Coverage Brean Capital Buy $8.00
2015-10-01 Reiterated Rating Brean Capital Buy $8.00
2015-08-11 Reiterated Rating Brean Capital Buy $8.00
2015-06-30 Initiated Coverage MLV & Co. Buy
2015-05-12 Reiterated Rating Brean Capital Buy $8.00
2015-04-28 Initiated Coverage MLV & Co. Buy $6.00
2015-03-12 Initiated Coverage Brean Capital Positive
2015-03-06 Set Price Target Brean Capital Buy $8.00
2015-02-18 Initiated Coverage Brean Capital Buy $8.00
2014-10-09 Reiterated Rating ING Group Buy
2014-09-08 Initiated H.C. Wainwright Neutral
2014-09-08 Initiated Coverage HC Wainwright Neutral
2014-08-08 Reiterated Rating Aegis Buy
2014-06-25 Reiterated Aegis Capital Buy $6 to $7
2014-06-25 Boost Price Target Aegis Buy $6.00 to $7.00
2014-05-27 Boost Price Target Aegis $6.00
2012-12-10 Reiterated Aegis Capital Buy $3 to $3.50
2012-08-23 Initiated Maxim Group Sell $0.25
2011-09-22 Initiated Morgan Joseph Buy $5
2016-06-22 Initiated Coverage Brean Capital Buy $8.00
2016-02-20 Reiterated Rating Brean Capital Buy $8.00
2016-01-29 Initiated Coverage Brean Capital Buy $8.00
2015-10-01 Reiterated Rating Brean Capital Buy $8.00
2015-08-11 Reiterated Rating Brean Capital Buy $8.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
GARR RICHARD CEO, President 1.67%  (1449804) CUR /
REGAL ONE CORP 1.49%  (1293814) CUR /
JOHE KARL Chief Scientific Officer 1.07%  (930373) CUR /
WESTREICH STANLEY 0.16%  (143281) CUR /
CONRON JOHN Chief Financial Officer 0.13%  (115492) CUR /
SMITH SANDFORD D 0.12%  (106952) AEGR / APRI / CUR / CYTK / QLTI /
Sohn Catherine A. 0.12%  (106952) CUR / JAZZ / LNDC /
OGILVIE SCOTT VARDE 0.10%  (86020) CUR /
OLDAKER WILLIAM CLYDE 0.04%  (33763) CUR / WFBI /
Daly Richard J Chief Executive Officer 0.03%  (23312) CPRX / CUR / SGYP /
LLOYD JONES JONATHAN BRIAN Chief Financial Officer 0.01%  (7859) CBRX / CUR /

Comments